Amendments to the Brief Description of the Figures

Please replace the paragraph beginning at page 5, line 4, with the following amended paragraph:

Figure 1A-1B — 1A and 1B: The synthesis of GD3 protein conjugates after ozone cleavage and reductive amination. Insert represents HPTLC of GD3 before (lane A) and after (lane B) the cleavage.

Please replace the paragraph beginning at page 6, line 11, with the following amended paragraph:

Figures ~~8A-1 and 8A-2~~ 8A - 8B

8A and 8B: Specificity of peak titer sera from patients immunized GM2-KLH + QS-21 vaccine determined by immune thin layer chromatography as described previously (3, Reference of the Third Series of Experiments). GM2 (A) and melanoma tissue ganglioside extract (B) were applied to TLC plates, incubated with sera from individual patients and stained with peroxidase-labeled goat anti-human IgM or IgG antibody. MAb 696 was used as positive control for GM2 and resorcinol stain for gangliosides.

Please replace the paragraph beginning at page 6, line

24, with the following amended paragraph:

Figure ~~8B~~ 8C — Inhibition of IgG reactivity of patient serum against GM2 and GD2. GM2 (A) and melanoma tissue ganglioside extract (B) were applied to HPTLC plates, incubated with serum from patient No. 2 and stained with peroxidase-labeled goat anti-human IgG antibody. 3ml Patient serum at a dilution of 1:50 was preincubated with either 150µg GM2 or 150µg GD2 prior to Immune staining.

Please replace the paragraph beginning at page 6, line 24, with the following amended paragraph:

Figures 9A, ~~and~~ 9B, 9C, and 9D — IgM and IgG antibody response in melanoma patients after immunization with GM2-KLH plus QS-21 vaccines. Sequential results for six patients receiving the 100 ug QS-21 dose are shown in Figures 9A and 9B ~~Figure 9a~~ and for six patients receiving the 200 ug dose in Figures 9C and 9D ~~Figure 9b~~. Note that one patient in each group received only four vaccinations and was taken off study due to disease progression. Arrows indicate the time of cyclophosphamide (Cy) and GM2-KLH plus QS-21 vaccine injections.

REMARKS

Claims 123 and 130-145 have been allowed in the subject application. Applicants hereinabove have amended the Brief Description of the Figures merely to make it consistent with the drawing changes required by the draftsperson in the Notice of Draftsperson's Patent Review mailed 6/10/1996 in connection with the above-identified application. Applicants note that the Brief Description of the Figures was previously amended on December 10, 1996.

If a telephone conference would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Amendment. However, if an additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: MAIL STOP ISSUE FEE, Commissioner for Patents, P.O. BOX 1450, Alexandria, VA 22313-1450.



September 14, 2005
John P. White — Date
Reg. No. 28,678